Marco Filetti
Cited by
Cited by
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ...
Journal for immunotherapy of cancer 7 (1), 1-11, 2019
The psychophysiology primer: a guide to methods and a broad review with a focus on human-computer interaction
BU Cowley, M Filetti, K Lukander, J Torniainen, A Helenius, L Ahonen, ...
Foundations and Trends in Human-Computer Interaction, 2016
Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: A real‐world transverse study
A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ...
The oncologist 24 (6), e327, 2019
Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients
A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ...
Clinical lung cancer 20 (4), 237-247. e1, 2019
Subliminal Salience Search Illustrated: EEG Identity and Deception Detection on the Fringe of Awareness
H Bowman, M Filetti, D Janssen, L Su, A Alsufyani, B Wyble
PLOS One 8 (1), e54258, 2013
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ...
Annals of Oncology 31 (12), 1746-1754, 2020
Countering countermeasures: detecting identity lies by detecting conscious breakthrough
H Bowman, M Filetti, A Alsufyani, D Janssen, L Su
PloS one 9 (3), e90595, 2014
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death …
A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ...
European Journal of Cancer 128, 17-26, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50%
A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ...
Cancer Immunology, Immunotherapy 69, 2209-2221, 2020
The cost of space independence in P300-BCI spellers
S Chennu, A Alsufyani, M Filetti, AM Owen, H Bowman
Journal of neuroengineering and rehabilitation 10 (1), 1-13, 2013
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ...
Journal for immunotherapy of cancer 8 (2), 2020
Predictive biomarkers for checkpoint inhibitor-based immunotherapy: the galectin-3 signature in NSCLCs
C Capalbo, G Scafetta, M Filetti, P Marchetti, A Bartolazzi
International journal of molecular sciences 20 (7), 1607, 2019
Immune-related adverse events of Pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes
A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ...
Clinical Lung Cancer 21 (6), 498-508. e2, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation
A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ...
Journal for immunotherapy of cancer 8 (2), 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ...
European Journal of Cancer 134, 19-28, 2020
Attention is more than prediction precision [Commentary on target article]
H Bowman, M Filetti, B Wyble, C Olivers
Behavioral and Brain Sciences 36 (3), 206-208, 2013
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and …
S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ...
European Journal of Cancer 142, 18-28, 2021
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
A Cortellini, A Leonetti, A Catino, P Pizzutillo, B Ricciuti, A De Giglio, ...
Clinical and Translational Oncology 22 (6), 844-851, 2020
Effective treatment of a platinum‑resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition
C Capalbo, F Belardinilli, M Filetti, C Parisi, M Petroni, V Colicchia, ...
Molecular and clinical oncology 9 (1), 30-34, 2018
Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: case report and literature review
R Falcone, M Roberto, M Filetti, E Anselmi, P Marchetti
Medicine 97 (3), 2018
The system can't perform the operation now. Try again later.
Articles 1–20